Peginterferon and ribavirin for hepatitis C
Abramowicz, M.
New England Journal of Medicine 356(12): 1270-1271; Author Reply 1271
2007
ISSN/ISBN: 0028-4793 PMID: 17378100 Document Number: 610904
Document emailed within 1 workday
Related Documents
Wong, J. B.; Nevens, F. 2002: Cost-effectiveness of peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin as initial treatment of chronic hepatitis C in Belgium Acta Gastro-Enterologica Belgica 65(2): 110-111Nunnari, G.; Montineri, A.; Portelli, V.; Savalli, F.; Fatuzzo, F.; Cacopardo, B. 2012: The use of peginterferon in monotherapy or in combination with ribavirin for the treatment of acute hepatitis C European Review for Medical and Pharmacological Sciences 16(8): 1013-1016
Roznovský, L.; Orságová, I.; Petrousová, L.; Mrázek, J.; Kloudová, A.; Kabieszová, L.; Kůrková, J.; Pospísek, M. 2010: Retreatment with peginterferon plus ribavirin in chronic hepatitis C patients: our own experiences Klinicka Mikrobiologie a Infekcni Lekarstvi 16(2): 73-75
Varghese, R.; Al-Khaldi, J.; Asker, H.; Fadili, A.A.; Al Ali, J.; Hassan, F.A. 2009: Treatment of chronic hepatitis C genotype 4 with peginterferon alpha-2a plus ribavirin Hepato-Gastroenterology 56(89): 218-222
Yu, J.; Liu, B.-w.; Lan, L.; Yuan, Y.; Zhang, H.; Jia, C.-h. 2010: Efficacy of peginterferon alpha-2a in combination with ribavirin in treatment of eldly patients with chronic hepatitis C Zhonghua Shi Yan he Lin Chuang Bing du Xue Za Zhi 24(5): 373-375
Muñoz, A.E. 2007: New strategies for a better use of peginterferon and ribavirin and new drugs with specifically-targeted antiviral therapy for chronic hepatitis C Acta Gastroenterologica Latinoamericana 37(2): 126-133
Bizid, S.; Ben Abdallah, H.; Kilani, I.; Mohamed, G.; Bouali, R.; Abdelli, N. 2013: Predictive factors of response to peginterferon and ribavirin in Tunisians patients with chronic hepatitis C: report of 141 cases La Tunisie Medicale 91(5): 327-331
Ayyub, M.A.; El-Moursy, S.A.; Khazindar, A.M.; Abbas, F.A. 2009: Successful treatment of chronic hepatitis C virus infection with peginterferon alpha-2a and ribavirin in patients with sickle cell disease Saudi Medical Journal 30(5): 712-716
Taskoparan, M.; Serin, E.; Gokturk, H.Savas.; Icer, M.Okan.; Abaci, K.; Ozer, B.; Zumrutdal, A.; Yilmaz, U. 2011: Early effect of peginterferon alpha-2b plus ribavirin treatment on blood pressure and insulin resistance in patients with chronic hepatitis C Hepato-Gastroenterology 58(107-108): 875-879
Nevens, F.; Van Vlierberghe, H.; D'Heygere, E.; Delwaide, J.; Adler, M.; Henrion, J.; Lenaerts, A.; Hendlisz, A.; Michielsen, P.; Bastens, B.; Brenard, R.; Laureys, A. 2010: A randomized, open-label, multicenter study evaluating the efficacy of peginterferon alfa-2a versus interferon alfa-2a, in combination with ribavirin, in naïve and relapsed chronic hepatitis C patients Acta Gastro-Enterologica Belgica 73(2): 223-228
Gheorghe, L.; Baculea, S. 2010: Cost-effectiveness of peginterferon alpha-2a and peginterferon alpha-2b combination regimens in genotype-1 naive patients with chronic hepatitis C Hepato-Gastroenterology 57(101): 939-944
Takagi, H.; Hoshino, T.; Naganuma, A.; Koitabashi, E.; Uehara, S.; Sakamoto, N.; Kudo, T.; Ryusaki, K.; Kakizaki, S.; Okamoto, H. 2013: Drug induced hypersensitivity syndrome by triple therapy of peginterferon alpha2b, ribavirin and telaprevir in patient with double positive for HBV and HCV Hepato-Gastroenterology 60(127): 1557-1560
Amarapurkar, D.N.; Patel, N.D.; Kirpalani, A.L. 2007: Monotherapy with peginterferon alpha-2b {12 kDa} for chronic hepatitis C infection in patients undergoing haemodialysis Tropical gastroenterology: official journal of the Digestive Diseases Foundation 28(1): 16-18
Hrycewycz, N.; Sandres, K.; Barange, K.; Pascal, J.P.; Izopet, J.; Payen, J.L. 2001: Eradication of hepatitis C virus after 3 months of interferon and ribavirin treatment in an a interferon non-responder patient with chronic hepatitis C Gastroenterologie Clinique et Biologique 25(11): 1041-1042
Saitta, C.; Pontisso, P.; Brunetto, M.R.; Fargion, S.; Gaeta, G.B.; Niro, G.A.; Picciotto, A.; Smedile, A.; Squadrito, G.; Raimondo, G. 2006: Virological profiles in hepatitis B virus/hepatitis C virus coinfected patients under interferon plus ribavirin therapy Antiviral Therapy 11(7): 931-934
Kumta, N.B.; Antani, D.N. 1983: Ribavirin trial in cases of infective hepatitis Indian Pediatrics 20(2): 99-103
Gunsar, F.; Akarca, U.S.; Ersoz, G.; Kobak, A.C.; Karasu, Z.; Yuce, G.; Ilter, T.; Batur, Y. 2005: Two-year interferon therapy with or without ribavirin in chronic delta hepatitis Antiviral Therapy 10(6): 721-726
Arase, Y. 2011: Combination therapy of PEG-interferon and ribavirin for chronic hepatitis C in Japan Nihon Rinsho. Japanese Journal of Clinical Medicine 69(Suppl 4): 191-195
Roberts, R.B.; Dickinson, G.M.; Heseltine, P.N.; Leedom, J.M.; Mansell, P.W.; Rodriguez, S.; Johnson, K.M.; Lubina, J.A.; Makuch, R.W. 1990: A multicenter clinical trial of oral ribavirin in HIV-infected patients with lymphadenopathy. the Ribavirin-LAS Collaborative Group Journal of Acquired Immune Deficiency Syndromes 3(9): 884-892
Shakeel Ahmad, J.; Ashfaa, A.; Habib Ahmad, J. 2014: Effect of standard interferon and ribavirin on haemoglobin level in hepatitis-C patients Journal of Ayub Medical College Abbottabad: Jamc 26(4): 510-512